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tors predicting improved survival; however in a multivariable
model, achieving a CR1 (p¼0.002) and undergoing allogeneic
SCT retained prognostic signiﬁcance (p¼0.01).
Conclusion: Leukemic transformation from CMML is asso-
ciated with poor outcomes. For eligible patients, induction
chemotherapy followed by allogeneic SCT seems to offer the
best chances for achieving durable remissions.217
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Universitätsmedizin Berlin, Berlin, GermanyAims: Allogeneic stem cell transplantation (alloSCT) in ﬁrst
complete remission (CR1) has become a standard of care for
many patients (pts) with intermediate or high risk acute
myeloid leukemia (AML). Furthermore, pts with relapsed
AML may be salvaged by re-induction and subsequent
alloSCT. Here, we analyzed the outcome of pts with AML
transplanted beyond CR1 at our center between 1996 and
2013.
Pts and Methods: 120 pts (50 female, 70 male) with a me-
dian age of 49 (19-72) years were retrospectively analyzed as
of June 30th, 2013. 92 pts had de novo AML and 28 pts had
secondary or therapy-related AML. 63 pts were in CR2
whereas 57 pts were refractory to re-induction therapy and
had active disease at the time of alloSCT. The SWOG/ECOG
cytogenetic risk proﬁle was favorable in 16 pts, intermediate
in 53 pts, and unfavorable in 34 pts (unknown: 11 pts, un-
determined: 6 pts). Conditioning consisted of a 12 Gy TBI-
basedmyeloablative regimen (MAC) in 51 pts. 61 pts received
reduced intensity conditioning (RIC: FLU/BU/ATG) and 9 pts
were conditioned using the FlamsaRIC protocol. A matched
related donor was available in 33 pts. 62 pts had a matched-
unrelated donor and 25 pts had a mismatched unrelated
donor.
Results: After a median follow-up of 39 (3-185) months, 44
pts are alive and in CR. Causes of death were relapse in 37 pts
or non-relapse mortality (NRM) in 36 pts. At 1, 3, and 5 years
after alloSCT projected overall survival (OS) or disease-free
survival (DFS) of the entire cohort was 50% (41-60%), 40%
(30-50%), and 39% (29-49%) or 48% (39-58%), 39% (30-49%),
or 38% (28-47%). At the same time points the cumulative
incidence of relapse (CIR) or NRM (CINRM)was 25% (19-35%),
31% (23-41%), and 32% (24-42%) or 25% (21-38%), 28% (21-
38%), or 30% (22-40%). In univariate analysis pts refractory to
re-induction therapy had a signiﬁcantly lower 3-year DFS
(26%) as compared to pts transplanted in CR2 (54%) (HR 1.8
(95%CI: 1.1-2.8), p¼0.01), due to an increased relapse rate
(40% vs 24%, p¼0.003). Similarly, an interval of 12 months
from diagnosis to alloSCT was predictive for a lower 3-year
DFS as compared to an interval of >12 months (21% vs 52%)
(HR 2.0 (95%CI: 1.2-3.3), p¼0.002), due to an increased
relapse incidence (47% vs 23%, p<0.001). All other factors
examined, i.e. gender, cytogenetic risk, AML subtype, age
group, type of conditioning, donor, or year of alloSCT, were
not predictive for OS, DFS, CIR, or CINRM. In multivariate
analysis, remission status and time from diagnosis to trans-
plantation were identiﬁed as independent prognosticators
for OS, DFS, and CIR.
Conclusions: In sum, our data indicate that pts with AML
beyond CR1 may be successfully salvaged by alloSCT. In
particular, pts transplanted in CR2 beneﬁt the most. Pts re-
fractory to re-induction may be candidates for alloSCT as
well. However, these pts have a poorer outcome due to a high
relapse rate irrespective of the cytogenetic risk proﬁle and
the conditioning regimen used.218
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Introduction: Patients with acute myeloid leukemia (AML)
refractory to induction chemotherapy have dismal progno-
ses. Although allogeneic stem cell transplant (allo-SCT)
